Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats

Galapagos (GLPG) stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people. RBC Capital Markets analyst Brian Abrahams says this is an important step for furthering Galapagos' point-of-care model for CAR-T drugs. CAR-T drugs involve removing a patient's immune cells and then genetically modifying them to find and destroy cancer cells.